Q2 EPS Estimates for Purple Biotech Raised by HC Wainwright

Posted by Brenda Bartman on May 20th, 2026

Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT – Free Report) – HC Wainwright upped their Q2 2026 EPS estimates for Purple Biotech in a report issued on Monday, May 18th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($0.98) per share for the quarter, up from their previous forecast of ($4.00). HC Wainwright currently has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Purple Biotech’s current full-year earnings is ($16.50) per share. HC Wainwright also issued estimates for Purple Biotech’s Q3 2026 earnings at ($1.73) EPS, Q4 2026 earnings at ($2.51) EPS, FY2026 earnings at ($5.31) EPS, FY2027 earnings at ($0.88) EPS, FY2028 earnings at ($0.15) EPS, FY2029 earnings at $0.07 EPS and FY2030 earnings at ($0.29) EPS.

Purple Biotech (NASDAQ:PPBT – Get Free Report) last issued its earnings results on Friday, May 15th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.29.

Several other brokerages also recently commented on PPBT. Weiss Ratings downgraded shares of Purple Biotech from a “sell (e+)” rating to a “sell (e)” rating in a research note on Monday, May 4th. Zacks Research raised shares of Purple Biotech from a “strong sell” rating to a “hold” rating in a research note on Monday, April 13th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Purple Biotech presently has a consensus rating of “Hold” and a consensus target price of $30.00.

Get Our Latest Stock Analysis on PPBT

Purple Biotech Stock Down 7.1%

Shares of NASDAQ PPBT opened at $3.51 on Wednesday. Purple Biotech has a 52 week low of $3.47 and a 52 week high of $29.00. The firm’s fifty day moving average is $4.14 and its 200 day moving average is $5.88. The company has a market cap of $4.49 million, a price-to-earnings ratio of -0.19 and a beta of 0.68.

Institutional Trading of Purple Biotech

A hedge fund recently bought a new stake in Purple Biotech stock. Virtu Financial LLC purchased a new stake in Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT – Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 48,993 shares of the company’s stock, valued at approximately $28,000. Virtu Financial LLC owned approximately 0.38% of Purple Biotech as of its most recent SEC filing. Institutional investors and hedge funds own 9.64% of the company’s stock.

Key Headlines Impacting Purple Biotech

Here are the key news stories impacting Purple Biotech this week:

Positive Sentiment: HC Wainwright lifted its FY2026 earnings estimate for Purple Biotech to ($5.31) per share from a prior forecast of ($16.50), implying a much smaller loss than expected. Purple Biotech analyst update
Positive Sentiment: The firm also raised its Q2 2026, Q3 2026, and Q4 2026 EPS estimates, suggesting improving expectations across the near-term pipeline outlook. Purple Biotech analyst update
Positive Sentiment: HC Wainwright increased longer-term estimates for FY2027, FY2028, FY2029, and FY2030, including a move to positive EPS in FY2029, which may signal growing confidence in the company’s future earnings trajectory. Purple Biotech analyst update
Neutral Sentiment: HC Wainwright reiterated its Buy rating and $30 price target, reinforcing a bullish stance but not adding new operational news. Purple Biotech analyst update
Neutral Sentiment: The stock recently traded near its 12-month low, so recent analyst optimism may be offset by broader weakness and the company’s very small market cap. Purple Biotech stock overview

About Purple Biotech

(Get Free Report)

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage.